Medivation (MDVN) : Tuesdays money flow indicated an uptick to downtick ratio was at 1.46. The total value of inflow transactions on upticks was $25.8 million, whereas, the total value of outflow trades on downticks was $17.7 million. The total money flow was $8.1 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $8.3 million. The total value of the trades done on upticks was $10.3 million. Downticks saw transactions worth $2 million. The total uptick to downtick ratio stood at 5.15, mildly in favor of the bulls. Medivation (MDVN) was trading with a -0.13% change over previous days close. It fell $0.08 during the day and reached $62.15. The stock was 0.08% compared to the previous weeks close.
The company Insiders own 3.54% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.41% . Institutional Investors own 90.64% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of 0.89%. In an insider trading activity, The officer (SVP, General Counsel & Crp Sec), of Medivation, Inc., Powell Andrew Kenneth William had unloaded 2,578 shares at $60.42 per share in a transaction on June 6, 2016. The total value of transaction was $155,763. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Shares of Medivation, Inc. rose by 0.63% in the last five trading days and 3.57% for the last 4 weeks. Medivation, Inc. is up 35.91% in the last 3-month period. Year-to-Date the stock performance stands at 28.57%.
Medivation (NASDAQ:MDVN): On Tuesdays trading session , Opening price of the stock was $62.59 with an intraday high of $62.64. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $62.05. However, the stock managed to close at $62.15, a loss of 0.13% for the day. On the previous day, the stock had closed at $62.23. The total traded volume of the day was 1,687,993 shares.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.